Triple Negative Breast Neoplasms

• 

  Subject Areas on Research

  • A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms Abraxane in multiple murine cancer models. 
  • A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer. 
  • A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery. 
  • Adipose stem cell crosstalk with chemo-residual breast cancer cells: implications for tumor recurrence. 
  • An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection. 
  • An unexpected alliance between stress responses to drive oncogenesis. 
  • Association of body composition with odds of breast cancer by molecular subtype: analysis of the Mechanisms for Established and Novel Risk Factors for Breast Cancer in Nigerian Women (MEND) study. 
  • Association of lipid profile biomarkers with breast cancer by molecular subtype: analysis of the MEND study. 
  • Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database. 
  • Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer. 
  • Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis. 
  • Blood-brain barrier-penetrating amphiphilic polymer nanoparticles deliver docetaxel for the treatment of brain metastases of triple negative breast cancer. 
  • Breast Cancer Biology: Clinical Implications for Breast Radiation Therapy. 
  • CaMKK2 in myeloid cells is a key regulator of the immune-suppressive microenvironment in breast cancer. 
  • Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer. 
  • Carbamate derivatives of colchicine show potent activity towards primary acute lymphoblastic leukemia and primary breast cancer cells-in vitro and ex vivo study. 
  • Carbohydrate Microarrays Identify Blood Group Precursor Cryptic Epitopes as Potential Immunological Targets of Breast Cancer. 
  • Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface. 
  • Circulating tumor cell analysis in metastatic triple-negative breast cancers. 
  • Clinicopathological Features of Triple-Negative Breast Cancer Epigenetic Subtypes. 
  • Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer. 
  • Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and "BRCAness" Mutations. 
  • Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling. 
  • Differential cellular localization of CELSR2 and ING4 and correlations with hormone receptor status in breast cancer. 
  • Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells. 
  • Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice. 
  • Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism. 
  • Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer. 
  • Epigenetic Switch-Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer. 
  • Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer. 
  • Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases. 
  • Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. 
  • IL26, a Noncanonical Mediator of DNA Inflammatory Stimulation, Promotes TNBC Engraftment and Progression in Association with Neutrophils. 
  • Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic Modalities for Targeting Rapidly Proliferating Breast Cancers. 
  • Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy. 
  • Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer. 
  • MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression. 
  • MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. 
  • Mesothelin expression is associated with poor outcomes in breast cancer. 
  • Metabolic Syndrome and Risk of Breast Cancer by Molecular Subtype: Analysis of the MEND Study. 
  • MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer. 
  • Mitophagy defects arising from BNip3 loss promote mammary tumor progression to metastasis. 
  • Multitargeted Nanoparticles Deliver Synergistic Drugs across the Blood-Brain Barrier to Brain Metastases of Triple Negative Breast Cancer Cells and Tumor-Associated Macrophages. 
  • Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set. 
  • Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer. 
  • Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNβ-Driven Antitumor Immunity. 
  • Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance. 
  • PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer. 
  • Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer. 
  • Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers. 
  • Post-irradiation morphoea of the breast: a case report and review of the literature. 
  • Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. 
  • Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer. 
  • Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45). 
  • Revealing targeted therapeutic opportunities in triple-negative breast cancers: a new strategy. 
  • Risk of positive nonsentinel nodes in women with 1-2 positive sentinel nodes related to age and molecular subtype approximated by receptor status. 
  • Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. 
  • Survival Outcomes Among Patients with Metastatic Breast Cancer: Review of 47,000 Patients. 
  • Syndecan-1 facilitates breast cancer metastasis to the brain. 
  • TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. 
  • TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. 
  • TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). 
  • Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response. 
  • Targeting Tumor Acidosis and Regulatory T Cells Unmasks Anti-Metastatic Potential of Local Tumor Ablation in Triple-Negative Breast Cancer. 
  • The LINK-A lncRNA activates normoxic HIF1α signalling in triple-negative breast cancer. 
  • The LINK-A lncRNA interacts with PtdIns(3,4,5)P3 to hyperactivate AKT and confer resistance to AKT inhibitors. 
  • The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion. 
  • Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study. 
  • Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2. 
  • Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq. 
  • Utilization of neoadjuvant chemotherapy in high-risk, node-negative early breast cancer. 
  • αB-crystallin: a novel regulator of breast cancer metastasis to the brain.